Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Dec 28;31(4):384-388.
doi: 10.31138/mjr.31.4.384. eCollection 2020 Dec.

Rheumatoid Arthritis: Defining Clinical and Ultrasound Deep Remission

Corominas Hèctor  1 , Ana Milena Millan  1 , Cesar Diaz-Torne  1
Affiliations
Review

Rheumatoid Arthritis: Defining Clinical and Ultrasound Deep Remission

Corominas Hèctor et al. Mediterr J Rheumatol. .

Abstract

The prognosis of patients with rheumatoid arthritis (RA) has improved substantially in the last two decades due to the appearance of biological therapies, but above all, due to the improvement in the strategy and management of the disease. Our goal in RA should be to achieve remission, or in its absence, the lowest inflammatory activity. Achieving remission will prevent from structural and functional damage highly associated with RA itself. Clinical remission is defined as the absence of significant signs and symptoms of inflammatory disease activity, as well as the abrogation of any signs of systemic inflammation. Currently, there are some controversies about remission. Which is the real remission? Which remission criteria should be used and when? Does clinical remission mean ultrasound remission? In the present review, we try to answer and put some light into it, focusing on clinical and ultrasound deep remission.

Keywords: Rheumatoid arthritis; clinical remission; ultrasound remission.

PubMed Disclaimer

References

    1. Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017. June;76(6):960–77. - PubMed
    1. Kavanaugh A, Fleischmann RM, Emery P, Kupper H, Redden L, Guerette B, et al. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. Ann Rheum Dis 2013. January;72(1):64–71. - PMC - PubMed
    1. Ruyssen-Witrand A, Guernec G, Nigon D, Tobon G, Jamard B, Rat AC, et al. Aiming for SDAI remission versus low disease activity at 1 year after inclusion in ESPOIR cohort is associated with better 3-year structural outcomes. Ann Rheum Dis 2015. September;74(9):1676–83. - PubMed
    1. Belmonte Serrano MÁ. Is the DAS28 Score the Most Adequate Method to Estimate Activity in Rheumatoid Arthritis? Clinimetric Considerations and Simulations Scenarios. Reumatol Clin 2008. September;4(5):183–90. - PubMed
    1. Wolfe F. Comparative usefulness of C-reactive protein and erythrocyte sedimentation rate in patients with rheumatoid arthritis. J Rheumatol 1997. August; 24(8):1477–85. - PubMed

LinkOut - more resources